InsiderTrades.com logo
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
From Traders Agency   |   Ad
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Click here now for the full details of this stock that’s set to rocket in the AI revolution…
Stephen Uden net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Stephen Uden Biography and Net Worth

Insider of Rallybio
Steve is a Co-Founder and Chief Operating Officer of Rallybio. He has more than 25 years of experience, serving in R&D leadership roles with prominent global pharmaceutical and biotech firms. Steve was previously Head of Research at Alexion Pharmaceuticals, where he led a series of collaborations and external alliances, and expanded its research base beyond antibodies to include small molecules, RNA-based therapies and broader protein engineering capabilities. Prior to Alexion, Steve led research and development groups in Japan for Wyeth and Novartis Oncology, and held positions of increasing responsibility at Pfizer in the U.K., Japan and the U.S.

Steve received his medical training at the University of London’s St. Thomas’ Hospital Medical School, and then practiced clinical and academic medicine within the U.K.’s National Health Service and at the University of Manchester.

OTHER THINGS WORTH KNOWING ABOUT ME:

My dream vacation is diving in Truk Lagoon.

My favorite charity is the RNLI – Royal National Lifeboat Institution.

My greatest non-work accomplishment is 21 years of service in the U.K. Army Reserve (though it was sort of a job.)

How old is Stephen Uden?

Dr. Uden is currently 66 years old. There are 2 older executives and no younger executives at Rallybio. The oldest executive at Rallybio is Dr. Martin W. MacKay Ph.D., Co-Founder & Executive Chairman, who is 68 years old. Learn More on Stephen Uden's age.

How do I contact Stephen Uden?

The corporate mailing address for Dr. Uden and other Rallybio executives is , , . Rallybio can also be reached via phone at 203-59-3820 and via email at [email protected]. Learn More on Stephen Uden's contact information.

Has Stephen Uden been buying or selling shares of Rallybio?

Stephen Uden has not been actively trading shares of Rallybio during the last ninety days. Most recently, on Wednesday, January 12th, Stephen Uden bought 5,000 shares of Rallybio stock. The stock was acquired at an average cost of $10.55 per share, with a total value of $52,750.00. Learn More on Stephen Uden's trading history.

Who are Rallybio's active insiders?

Rallybio's insider roster includes Jeffrey Fryer (Insider), Martin Mackay (CEO), and Stephen Uden (Insider). Learn More on Rallybio's active insiders.

Stephen Uden Insider Trading History at Rallybio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/12/2022Buy5,000$10.55$52,750.00View SEC Filing Icon  
See Full Table

Stephen Uden Buying and Selling Activity at Rallybio

This chart shows Stephen Uden's buying and selling at Rallybio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Rallybio Company Overview

Rallybio logo
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
Read More

Today's Range

Now: $1.65
Low: $1.54
High: $1.72

50 Day Range

MA: $1.81
Low: $1.47
High: $2.98

2 Week Range

Now: $1.65
Low: $1.23
High: $9.14

Volume

319,673 shs

Average Volume

1,318,665 shs

Market Capitalization

$62.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
From Traders Agency   |   Ad
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Click here now for the full details of this stock that’s set to rocket in the AI revolution…